Dyslipidaemia versus endothelial dysfunction: Which is more important in the development of vascular disease?

International Journal of Clinical Practice, Supplement

Volumn , Issue 137, 2003, Pages 5-14

  Ferrannini, Ele ^b   Tuomilehto, Jaakko ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; ALPHA TOCOPHEROL; ANGIOTENSIN; ANTILIPEMIC AGENT; ANTIOXIDANT; APOLIPOPROTEIN; ASCORBIC ACID; BRADYKININ; CHOLESTEROL ABSORPTION INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; ENDOTHELIUM DERIVED RELAXING FACTOR; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NATRIURETIC PEPTIDE TYPE C; NITRIC OXIDE; PADGEM PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROSTACYCLIN; PROSTAGLANDIN H2; THROMBOXANE A2; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOACTIVE AGENT; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ARTERY ENDOTHELIUM; CONFERENCE PAPER; DYSLIPIDEMIA; ENDOTHELIUM LESION; EPIDEMIOLOGICAL DATA; GENETIC ANALYSIS; HUMAN; ISCHEMIC HEART DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; VASCULAR DISEASE;

ENDOTHELIUM, VASCULAR; HUMANS; HYPERLIPIDEMIAS; VASCULAR DISEASES;

EID: 0242511884     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (57)

1. WHO. World Health Report 2002. Geneva: World Health Organization, 2002.
2. Kahn HA, Dawber TR. The development of coronary heart disease in relation to sequential biennial measures of cholesterol in the Framingham study. J Chronic Dis 1966; 19: 611-620.
3. Keys A, Aravanis C, Blackburn HW et al. Epidemiological studies related to coronary heart disease: characteristics of men aged 40-59 in seven countries. Acta Med Scand 1966; Suppl 460: 1-392.
4. Neaton JD, Blackburn H, Jacobs D et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152: 1490-1500.
5. LaRosa JC. Understanding risk in hypercholesterolemia. Clin Cardiol 2003; 26: 13-16.
6. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
7. Goldstein JL, Brown MS. Lipoprotein receptors, cholesterol metabolism, and atherosclerosis. Arch Pathol 1975; 99: 181-184.
8. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002; 8: 1257-1262.
9. Koenig W. Inflammation and coronary heart disease: an overview. Cardiol Rev 2001; 9: 31-35.
10. Vakkilainen J, Steiner G, Ansquer JC et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003; 107: 1733-1737.
11. Gordon T, Castelli WP, Hjortland MC et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707-714.
12. Packard C, Nunn A, Hobbs R. High density lipoprotein: guardian of the vascular system? Int J Clin Pract 2002; 56: 761-771.
13. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991; 11: 2-14.
14. Walldius G, Jungner J, Holme I et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-2033.
15. Ballantyne CM. Familial hypercholesterolaemia: optimum treatment strategies. Int J Clin Pract 2002; Suppl 130: 22-26.
16. Lee CY, Krimbou L, Vincent J et al. Compound heterozygosity at the sphingomyelin phosphodiesterase-1 (SMPD1) gene is associated with low HDL cholesterol. Hum Genet 2003; 112: 552-562.
17. Attie AD, Kastelein JP, Hayden MR. Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. J Lipid Res 2001; 42: 1717-1726.
18. McKenney JM. Pharmacologic characteristics of statins. Clin Cardiol 2003; 26: III32-III38.
19. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-1357.
20. Shepherd J, Cobbs SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
21. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622.
22. Pfeffer MA, Sacks FM, Moye LA et al. Cholesterol And Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators. Am J Cardiol 1995; 76: 98C-106C.
23. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
24. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.
25. Robins SJ, Collins D, Wittes JT et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001; 285: 1585-1591.
26. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-1245.
27. Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002; 105: 546-549.
28. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168-175.
29. Drexler H, Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol 1999; 31: 51-60.
30. Barakat A, Lieu D. Differential responsiveness of vascular endothelial cells to different types of fluid mechanical shear stress. Cell Biochem Biophys 2003; 38: 323-343.
31. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906.
32. Zeiher AM, Krause T, Schachinger V et al. Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. Circulation 1995; 91: 2345-2352.
33. Hollenberg SM, Klein LN, Parrillo JE et al. Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation 2001; 104: 3091-3096.
34. Kuvin JT, Pater AR, Sliney KA et al. Peripheral vascular endothelial function testing as a noninvasive indicator of coronary artery disease. J Am Coll Cardiol 2001; 38: 1843-1849.
35. Perticone F, Ceravolo R, Notarangelo L et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191-196.
36. Anderson TJ, Vehata A, Gerhard MD et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 1235-1241.
37. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-1818.
38. Pasceri V, Cheng JS, Willerson JT et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 2531-2534.
39. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
40. Kobayashi N, Tsurya Y, Iwasawa T et al. Exercise training in patients with chronic heart failure improves endothelial function predominantly in the trained extremities. Circ J 2003; 67: 505-510.
41. Neunteufl T, Priglinger U, Heher S et al. Effects of vitamin E on chronic and acute endothelial dysfunction in smokers. J Am Coll Cardiol 2000; 35: 277-283.
42. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23-33.
43. Yusuf S, Dagenais G, Pogue J et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 154-160.
44. Anderson TJ, Meredith IT, Yeung AC et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332: 488-493.
45. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-1719.
46. Laufs U, Gertz K, Dirnagl U et al. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 2002; 942: 23-30.
47. Pelat M, Dessy C, Massion P et al. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo. Circulation 2003; 107: 2480-2486.
48. Ikeda Y, Young LH, Lefer AM. Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats. J Cardiovasc Pharmacol 2003; 41: 649-656.
49. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653-1659.
50. Lee AF, Dick JB, Bonnar CE, Struthers AD. Lisinopril improves arterial function in hyperlipidaemia. Clin Sci (Lond) 1999; 96: 441-448.
51. Caballero AE, Saouad R, Lim SC et al. The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 2003; 52: 173-180.
52. Neve BP, Fruchart JC, Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol 2000; 60: 1245-1250.
53. Delerive P, Martin-Nizard F, Chinetti G et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999; 85: 394-402.
54. Hoerger TJ, Bala MV, Bray JW et al. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 1998; 82: 61-65.
55. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-467.
56. Fodor JG, Frohlich JJ, Genest JJ Jr, McPherson PR. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. CMAJ 2000; 162: 1441-1447.
57. Shepherd J, Hunninghake DB, Barter P et al. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol 2003; 91: 11C-17C.